Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020


#30179

220pages

GlobalData

$ 3000

In Stock


GlobalData's pharmaceutical report, Prostate Cancer Spain Drug Forecasts and Treatment Analysis to 2020. The report is an essential source of information and analysis on the Spanish prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the Spanish prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the Spanish prostate cancer therapeutics market, highlighting the opportunity for future players. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

Scope

The scope of the report includes: 

  • An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized Spanish prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020. 
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.
  • Analysis of unmet need in the market and target product profiles including opportunity for target products. 
  • Technology trends analytic framework to assess the strength of the pipeline. 
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
  • Analysis of the current and future market competition in the Spanish Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
  • Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in Spain.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the Spanish prostate cancer therapeutics market. 
  • Understanding the treatment preferences of physicians for each disease state and across treatment flow.
  • Accessing market sizing forecasts and quantified growth opportunities in the Spanish prostate cancer therapeutics market up to 2020.
  • Quantifying the patient population in the Spanish to better design product pricing and launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products.
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
  • Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
  • Track drug sales in the Spanish prostate cancer therapeutics market from 2001 to 2020.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the Spanish prostate cancer therapeutics market landscape? Identify, understand and capitalize.
Table of contents

1 Prostate Cancer: Executive Summary
1.1 The Prostate Cancer Therapeutics Market was Driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy
1.2 The Current Competition in the Spanish Prostate Cancer Therapeutics Market is Weak as None of the Drugs Completely Addressed the Unmet Needs
1.3 The Prostate Cancer Pipeline is Strong with Many Novel First-in-class Molecules in Late-stage Clinical Development
1.4 High Unmet Needs Exist in the Prostate Cancer Therapeutics Market in terms of Efficacy and Safety

2 Disease Overview
2.1 Overview
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System
2.1.2 Jewett-Whitmore system
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Localized or Locally Advanced Prostate Cancer
2.4.2 Metastatic Prostate Cancer
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Prostate Specific Antigen Test
2.5.3 Transrectal Ultrasound
2.5.4 Prostate Biopsy
2.6 Pathology
2.6.1 Grading
2.7 Treatment
2.7.1 Watchful Waiting
2.7.2 Radiation therapy
2.7.3 Surgery
2.7.4 Hormone therapy
2.7.5 Chemotherapy Options
2.7.6 Other Treatments Being Studied
2.8 Treatment Guidelines

3 Market Characterization
3.1 Spain
3.1.1 Market Size
3.1.2 Drivers and Barriers
3.1.3 Impact on the Market
3.1.4 Forecasts
3.1.5 Drug Sales
3.1.6 Pricing and Reimbursements

4 Competitor Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.3 Current Competitor Assessment
4.2 Launch Analysis and Sales Forecasts
4.3 Product Profiles
4.3.1 Taxotere (docetaxel)
4.3.2 Casodex (Bicalutamide)
4.3.3 Zoladex (Goserelin)
4.3.4 Eligard (leuprolide acetate)
4.3.5 Firmagon (degarelix)
4.3.6 Novantrone (Mitoxantrone hydrochloride)
4.3.7 Emcyt (estramustine)
4.3.8 Trelstar (triptorelin)
4.3.9 Eulexin
4.3.10 Delestrogen
4.3.11 Gynodiol
4.3.12 Estrace tablet
4.3.13 Tace
4.3.14 Nilandrone
4.3.15 Premarin
4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol

5 Pipeline Assessment
5.1 Overview83
5.2 Pipeline Analysis by Phase of Development 84
5.3 Pipeline by Mechanism of Action 85
5.4 Strategic Pipeline Assessment 86
5.4.1 Technology Trends Analytical Framework 86
5.5 Trends in Prostate Cancer Pipeline 87
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 87
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 87
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 88
5.6 Partners in Research and Development 88
5.6.1 Licensing Agreements by Phase of Development 89
5.6.2 Licensing Agreements by Geography 92
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 92
5.7 Most Promising Drugs Profiles 93
5.7.1 Provenge (sipuleucel-T) 95
5.7.2 Jevtana (cabazitaxel) 97
5.7.3 Aflibercept (VEGF Trap) 99
5.7.4 Ipilimumab 101
5.7.5 Abiraterone Acetate (CB7630) 104
5.7.6 Zibotentan (ZD4054) 107
5.7.7 Sprycel (dasatinib) 109
5.7.8 MDV3100 111
5.8 Prostate Cancer Pipeline Pre-clinical Phase 114
5.9 Prostate Cancer Pipeline Phase I 116
5.10 Prostate Cancer Pipeline Phase II 119
5.11 Prostate Cancer Pipeline Phase III 128
5.12 Key Takeaway 130

6 Unmet Need and Target Product Profile 131
6.1 Unmet Need 133
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 133
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 134
6.2 Opportunity for Target Product 135
6.3 Target Product Profile 138
6.3.1 Ideal Characteristics 138
6.3.2 Target Product Description 139
6.4 Key Takeaway 139

7 Strategic Assessment 140
7.1 Key Events Impacting the Future Market 140
7.2 Market Impact Analysis 141
7.3 Future Market Scenario 141
7.4 Company Analysis 142
7.4.1 Market Leadership 142
7.4.2 Future Players in the Market 143
7.5 Key Takeaway 143

8 Company Profiles 144
8.1 Sanofi-aventis 144
8.1.1 Business Description 144
8.1.2 Financial Overview 146
8.1.3 SWOT Analysis 146
8.1.4 Oncology Focus 151
8.2 Pfizer Inc. 152
8.2.1 Business Description 152
8.2.2 Financial Overview 153
8.2.3 SWOT Analysis 153
8.2.4 Oncology Focus 159
8.3 AstraZeneca 161
8.3.1 Business Description 161
8.3.2 Financial Overview 162
8.3.3 SWOT Analysis 163
8.3.4 Oncology Focus 167
8.4 Bristol-Myers Squibb 169
8.4.1 Business Description 169
8.4.2 Financial Overview 170
8.4.3 SWOT Analysis 170
8.4.4 Oncology Focus 175
8.5 Medivation 177
8.5.1 Business Description 177
8.5.2 SWOT Analysis 177
8.5.3 Oncology Focus 180
8.6 Takeda Pharmaceuticals 180
8.6.1 Business Description 180
8.6.2 SWOT Analysis 181
8.7 Dendreon Corporation 183
8.7.1 Business Description 183
8.7.2 SWOT Analysis 183
8.8 Johnson and Johnson 186
8.8.1 Business Description 186
8.8.2 SWOT Analysis 188
8.8.3 Oncology Focus 194
8.9 Auron Healthcare GmbH 195
8.9.1 Business Description 195
8.10 Oncogenex Pharmaceuticals, Inc. 195
8.10.1 Business Description 195
8.11 Agennix AG 195
8.11.1 Business Description 195
8.12 GTx, Inc. 196
8.12.1 Business Description 196
8.13 GlaxoSmithKline plc. 196
8.13.1 Business Description 196
8.13.2 Financial Overview 197
8.13.3 SWOT Analysis 197
8.13.4 Oncology Focus 203

9 M&A Analysis 205
9.1 Key Highlights 205
9.2 Key Deals Analysis 207
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 207
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 207
9.2.3 Tolmar Holding Acquires QLT USA from QLT 207
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 207
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 207
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 208
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 208
9.2.8 GPC Biotech Merges with Agennix 208
9.2.9 Eli Lilly Acquires ImClone 208
9.2.10 BBM Holdings Acquires YM BioSciences 208
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 209
9.3 M&A Deals by Geography 209
9.4 M&A Deals by Deal Size 210

10 Expert Opinion 211
10.1 Spain 211

11 Appendix 212
11.1 Market Definitions 212
11.2 Abbreviations 212
11.3 Research Methodology 214
11.3.1 Coverage 215
11.3.2 Secondary Research 215
11.3.3 Forecasting 215
11.3.4 Primary Research 218
11.3.5 Expert Panel validation 218
11.3.6 Contact Us 218
11.3.7 Disclaimer 218
11.3.8 Sources 219
1.1 List of Tables
Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 11
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14
Table 3: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2001-2009 21
Table 4: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001-2009 22
Table 5: Prostate Cancer Therapeutics Market, Spain, Patient Volume (000s), 2001-2009 24
Table 6: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (000s), 2001-2009 25
Table 7: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2009-2020 29
Table 8: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2009-2020 30
Table 9: Prostate Cancer Therapeutics Market, Spain, Patient Volume (000s), 2009-2020 31
Table 10: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (000s), 2009-2020 33
Table 11: Prostate Cancer Therapeutics Market, Spain, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010 37
Table 12: Prostate Cancer Therapeutics Market, Spain, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2011-2020 37
Table 13: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2010 39
Table 14: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2011-2020 39
Table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 42
Table 16: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 43
Table 17: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 44
Table 18: Prostate Cancer, Spain, Benchmarking Major Marketed Products, 2010 48
Table 19: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 54
Table 20: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 61
Table 21: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 62
Table 22: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 63
Table 23: Prostate Cancer, Global, Licensing Agreements, 2009-2010 91
Table 24: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 93
Table 25: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 93
Table 26: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 114
Table 27: Prostate Cancer, Global, Phase I Pipeline, August 2010 116
Table 28: Prostate Cancer, Global, Phase II Pipeline, August 2010 119
Table 29: Prostate Cancer, Global, Phase III Pipeline, August 2010 128
Table 30: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 138
Table 31: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 139
Table 32: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 194
Table 33: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 195
Table 34: Prostate Cancer, Global, M&A Deals by Geography, 2010 2051.2 List of Figures
Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 20
Figure 2: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2001-2009 21
Figure 3: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001-2009 22
Figure 4: Prostate Cancer Therapeutics Market, Spain, Patient Volume (000s), 2001-2009 23
Figure 5: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (000s), 2001-2009 25
Figure 6: Prostate Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2009 27
Figure 7: Prostate Cancer Therapeutics Market, Spain, Historical Events Impact on the Market, 2010 28
Figure 8: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2009-2020 29
Figure 9: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2009-2020 30
Figure 10: Prostate Cancer Therapeutics Market, Spain, Patient Volume (000s), 2009-2020 31
Figure 11: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (000s), 2009-2020 33
Figure 12: Prostate Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2009-2020 35
Figure 13: Prostate Cancer Therapeutics Market, Spain, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 36
Figure 14: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020 38
Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 45
Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 46
Figure 17: Prostate Cancer Therapeutics Market, Spain, Sales Forecast by Therapies, 2001-2020 47
Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 49
Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 51
Figure 20: Prostate Cancer, Spain, Taxotere, Sales ($m), 2004-2020 52
Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 53
Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 57
Figure 23: Prostate Cancer, Spain, Casodex, Sales ($m), 1995-2020 58
Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 59
Figure 25: Prostate Cancer, Spain, Zoladex, Sales Forecast ($m), 1998-2020 60
Figure 26: Prostate Cancer, Global, Eligard , Chemical Structure 61
Figure 27: Prostate Cancer, Spain, Leuprolide (Eligard), Sales Forecast ($m), 2005-2020 64
Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure 65
Figure 29: Prostate Cancer, Spain, Firmagon, Sales Forecast ($m), 2009-2020 67
Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure 68
Figure 31: Prostate Cancer, Spain, Mitoxantrone, Sales Forecast ($m), 2001-2020 70
Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure 70
Figure 33: Prostate Cancer, Spain, Estramustine, Sales Forecast ($m), 2001-2020 71
Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure 72
Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure 73
Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 75
Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 77
Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure 78
Figure 39: Prostate Cancer, Global, Tace, Chemical Structure 79
Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 80
Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure 81
Figure 42: Prostate Cancer, Spain, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 82
Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 83
Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 84
Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 85
Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 86
Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 87
Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 89
Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 92
Figure 50: Prostate Cancer, Spain, Provenge, Sales Forecast ($m), 2012-2020 96
Figure 51: Prostate Cancer, Spain, Jevtana, Sales Forecast ($m), 2011-2020 98
Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 99
Figure 53: Prostate Cancer, Spain, Aflibercept, Sales Forecast ($m), 2014-2020 101
Figure 54: Prostate Cancer, Spain, Ipilimumab , Sales Forecast ($m), 2014-2020 103
Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 104
Figure 56: Prostate Cancer, Spain, Abiraterone, Sales Forecast ($m), 2013-2020 106
Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 107
Figure 58: Prostate Cancer, Spain, Zibotentan , Sales Forecast ($m), 2013-2020 109
Figure 59: Prostate Cancer, Spain, Sprycel , Sales Forecast ($m), 2013-2020 110
Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure 111
Figure 61: Prostate Cancer, Spain, MDV3100 , Sales Forecast ($m), 2013-2020 113
Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 131
Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 132
Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 132
Figure 65: Prostate Cancer, Spain, Prostate Cancer, Opportunity and Unmet Need, 2010 133
Figure 66: Prostate Cancer, Spain, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 136
Figure 67: Prostate Cancer, Spain, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 137
Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market 140
Figure 69: Prostate Cancer, Spain, Implications for Future Market Competition, 2010 141
Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010 143
Figure 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 144
Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 145
Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 146
Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 151
Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 153
Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 159
Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 160
Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 162
Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 163
Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 167
Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 167
Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 168
Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 169
Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 170
Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 175
Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 176
Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 177
Figure 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 181
Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 183
Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 188
Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 194
Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 197
Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 203
Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 204
Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 209
Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 210
Figure 97: Prostate Cancer, Spain, Key Data Inputs from KOL Interviews, July 2010 211
Figure 99: GlobalData Market Forecasting Model 217